The 6th International Cell & Gene Therapy China Summit & Exhibition (CGCS2025), hosted by Touch界 Biotechnology, will be held at the Yangtze River International Conference Center in Nanjing from May 28 to May 30. This summit will bring together top experts and industry leaders from around the world. Dr. Haisheng Zhang, founder and CEO of Signet Therapeutics, will attend as a special guest.Delivered a keynote speech titled "The Role of Organoids + AI in Disease Modeling and New Drug Development" at the Organoids Special Forum on May 29.。
It is reported that the CGCS conference is committed to becoming the "industry barometer" of cell and gene therapy. The CGCS 2025 - 6th International China Summit & Exhibition on Cell and Gene Therapy, hosted by Touch-Bio, is expected to bring together 250+ top global speakers, 6000+ industry professionals for offline participation, and 10000+ online global audience members, striving to inject more vitality into the industry.
About SIGNET
SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and accredited as a National High-tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since completed nearly 220 million yuan in financing and project funding. Currently, the company has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has successively received IND approvals from the U.S. FDA and China’s NMPA, along with Orphan Drug Designation and Fast Track Designation from the U.S. FDA. Phase I clinical trials are currently underway at the Peking University Cancer Hospital.
Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "full of hope, studying things to acquire knowledge." The company leverages patient-derived organoid disease models that closely resemble genomic characteristics for critical roles in drug efficacy evaluation and novel target discovery. By integrating AI-powered screening, synthesis, and optimization of small molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has approximately 1,500 square meters of R&D space and 500 square meters of animal laboratory facilities. Signet Therapeutics' organoid platform not only supports its internal drug pipeline but also actively empowers large pharmaceutical enterprises in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.
1
END
1
